Chemotherapy - Adriamycin (Doxorubicin)

Generic Name: Doxorubicin

Other Brand Name: Rubex

Adriamycin is a chemotherapy drug that is administered for the treatment of several types of cancer, including multiple myeloma, bladder cancer, breast cancer, leukemia, and lymphomas. It functions as an antineoplastic, cytotoxic drug, meaning that it is toxic to rapidly growing cells, such as tumors.

This drug is used for both Hodgkin’s and Non-Hodgkins Lymphomas. It is commonly used in conjunction with other chemotherapy drugs in the following regimens:

  • ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
  • CHOP (cytoxan, adriamycin, oncovin, prednisone)
  • Stanford-V (adriamycin, mustargen, bleomycin, vinblastine, oncovin, etoposide, prednisone)
  • BEACOPP (bleomycin, etoposide, adriamycin, cytoxan, oncovin, prednisone, procarbazine)

Drug Administration

Adriamycin is administered intravenously (IV) by one of two methods. A nurse may inject the drug directly into the IV tube over the course of several minutes or they may use a continuous infusion pump. However, due to adriamycin’s toxic nature, it should only be injected into a vein, not an artery. Nurses should monitor patients closely during administration to ensure that there is no swelling or redness at the injection site, which could indicate damage.

Side Effects

Common side effects include pain at the IV site, nausea, neutropenia and leukopenia (low blood counts), alopecia (hair loss), and the development of sores on the body.

Some less common side effects include darkening of the nail beds and skin, as well as diarrhea and swelling in the hands and feet. Adriamycin may also turn the urine red as it is filtered from the body, but this is usually not blood. This drug can also cause infertility, so talk to your doctor if you are planning on having a family.

The most serious side effects are long term. These include heart problems and secondary cancers, especially leukemia. Your doctor should monitor your health after finishing treatment to ensure that these symptoms do not occur.

For more information on Hodgkin's Lymphoma, please see the following pages:

For more information on Non-Hodgkin's Lymphoma, please see the following pages:

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap